FIR haplodeficiency promotes splicing to pyruvate kinase M2. According to a study published on Oncotarget Journal, the results was achieved using six-plex tandem mass tag quantitative proteomic analysis in the thymic lymphoma tissues of mice. The paper was published on the issue No. 40, Volume 8 of the journal. Watch this video on Youtube.
The study was prompted with the importance of converting pyravate kinase M1 to PKM2 during metabolism of glucose. PKM2 is found in cancer tissue while PKM1 is found in normal tissues. This study reveals the role of haplodeficiency of FUSE-binding protein-interacting repressors (FIR) in the process. The study further revealed that cancers were not able to regulate PKM2 yet they were still able to regulate PKM1. The research, which was conducted by a team of scientists that included Asako Kimura, Nokuko Tanaka, and Toshinari Minamoto, also revealed that the conversion of PKM1 to PKM2 was higher in mice tissues that were FIR+/-TP53-/-. In addition, the researchers concluded from the research that FIR and its spliceosomes could form ideal targets for targeted cancer therapies. The spliceosomes includes T-ALL. This information was originally reported on Research Gate as explained in this link https://www.researchgate.net/publication/320295957_oncotarget-08-67955
In other news, Oncotarget has increased the number of the issues it publishes from one to two every week. This is in response to the increasing number of researchers and scientists who are requesting the journal to publish their works. The journal will continue to remain open-source and will be available to any medicine enthusiast to read from a number of platforms. The platforms are mainly high profile scientific indexes and archives. They include BOISIS Previews, EMBASE, Biological Abstracts, Scopus, Science Citation Index Expanded, PubMed, PubMed Central, and ISI/Wed of Science. Oncotarget will also work closely with the National Library of Medicine to submit its issues to PubMed. This collaboration will greatly reduce the number of days it takes to publish the issues. Learn more about Oncotarget at Eurekalert.org.
Oncotarget is a peer-reviewed open access bio-medical journal. The publication covers all aspects of oncology, including topics such as autophagy, pathology and chromosomes, aging, and immunology and microbiology. Since its launch in 2010, the journal has published almost four hundred issues. Its first seven volumes had 324 issues. The increase of Oncotarget’s publication frequency will see the number of issues it publishes per year increase from 52 to over 104 issues.
Many physicians have committed themselves to researching about cancer therapies. Their primary objective is to come up with more effective ways of providing treatment in a less invasive manner. Mikhail Blagosklonny is among the most accomplished professionals, majoring in oncology and hematology. He is recognized globally for his dedication in carrying out clinical trials, which are meant to enhance therapies for cancer patients. When you talk of oncology or cancer, Mikhail’s name comes into the minds of many people; his undying efforts can never go unnoticed. Mr. Mikhail Blagosklonny spends much of his time at The Roswell Park Cancer Institute, where he joins hands with his fellow experts in attending to their patients.
What Discovery of Rapamycin Means to Dr. Mikhail
Discovering of Rapamycin’s healing properties marked a significant milestone in Mikhail’s oncology research. This is particularly because Rapamycin plays a crucial role in preventing tissue rejection after a patient successfully undergoes an organ transplant. Dr. Mikhail appreciates that Rapamycin proves quite useful when treating hemolytic-uremic syndrome. This is because it reduces the degree of toxicity after a kidney transplant. Apart from that, Rapamycin also prevents any chances of the new organ getting rejected by the body. There is a piece of writing that had been done on Philly Purge, where Dr. Blagosklonny explained on further benefits of Rapamycin. He indicated that it helps a lot in improving an individual’s general wellness.
How Mikhail Blagosklonny Intends to Drive His Campaign in Oncology
Dr. Mikhail Blagosklonny is a man with a big heart, ad he has grown to be recognized as a philanthropist. Blagosklonny works towards ensuring that everyone receives quality treatment regardless of wherever they come from or their financial status. The professor who lives an average life primarily focuses on the study of cancer and aging. Blagosklonny seeks to understand the relationship between cancer and age, now that the condition seems to be widespread among people above a particular age. His initiatives in the research sector yield results that are, and will remain useful in the oncology sector. His role also involves inspiring his students, something that has already given him a legacy. Mikhail’s expertise gives him confidence and enables him to maintain a high rank as an inspiration to many.
Impacting Oncology by Ensuring Cost-Effectiveness
As much as most doctors are concerned about improving cancer treatment, there is still more to be done to ensure that the procedures will no longer be as agonizing as they have been. At the same time, Blagosklonny is seeking to figure out how they can get rid of cancerous cells without meddling with the normal cells that are responsible for recovering the body and the mind after an individual has undertaken years of treatment of malignant cells. Mr. Mikhail does his best to achieve the best results and at the same time improve cancer treatment procedures. He believes that time is soon coming when these kinds of therapies will no longer be categorized as a luxury treatment because they will be affordable for everyone.
It is not a surprise that any aspect of life could be sought out without the necessity of manual efforts. This has been due to the effort of the different domains, making it easier for their products and services to have online access. Similarly, the healthcare sector is no different. An example of the technological advancements in this sector is the Oncortarget Research Journal.Oncortaget seeks to help healthcare personnel and medics to share helpful information and findings through their research journal. It is majorly focused on the deep oncology-related research. This journal was created in 2010 and then got published by impact journals having Andrei V. Gudkov and Mikhail Blagosklonny as its head editors. The Oncortarget is published weekly but this can be compromised in presence of a special request.Inspiration to come up with this medical journal was to maximize awareness of scientific findings and therefore boosting the significance of research through insightful critics.
This initiative has proven worthwhile especially because apparently the unnecessary costs due to negligence have gone down and many lives are not at stake anymore. The ultimate aim of Oncortarget is to create a disease-free world and to eradicate major deadly illnesses putting cancer in the top least.All forms of cancer have now been put to the limelight. The journal has been able to gather sufficient resources necessary for issuing therapy and treatment guidelines for cancer patients. The medics involved have come up with rare and specific strategies which would eventually improve the management of those affected by cancer.The fact that the journal’s researchers are from vast backgrounds means that whatever initiatives are put in place is of standard quality.
Being united by the same goal, a passion for sharing cancer research has been of great achievement not only to the researchers but also the healthcare sector at large.Being a free-to-all publication has steered public attention which is necessary for its growth. There have been positive responses on the brilliant setups which have played a great role in motivating the researchers who are on the potential cancer therapy case.IntegraGen, a company that is based on transforming biological samples data into genomic information has been a major part of the Oncortarget scheme. After thorough research, IntraGen released results of their recent tumor-related research through Oncortarget. This is just but one of the many significant scientific outcomes that the journal has brought to realization.
Oncotarget is an open access journal that was founded in 2010 and published by Impact Journals. Upon its establishment, it devoted itself to providing reliable information about the examination and treatment of cancer. It remains committed to issuing information related to the medical field.Finding the latest news of different medical fields can sometimes be located in expensive magazines and newsletters that are owned by unconventional sources. It is challenging to find such information in a university or college that has not subscribed to any of these news articles. Oncotarget is an international, peer-reviewed online news channel that touches on the recent news related to oncology. A reader can quickly access it and read more about different oncology topics.
Although its name has a prefix suggesting a subject primarily focused on oncology, it also publishes other medical topics such as microbiology, endocrinology, cell biology, neuroscience, pharmacology, the aging process, cardiology, immunology, metabolism, among others. The journal also delves into the effects of management programs as well as therapeutic agents in the life of a patient. It also compares new and previous therapy methodologies using existing evidence to determine their efficacy, usability, and acceptance.This free access journal is released on a weekly basis on an online platform. Sometimes the journal is printed on special demand. The journal’s mission is to share information quickly and widely.
In doing so, it participates in medical discoveries and improving human health all over the world.Oncotarget won the Lasker Award back in 2016 for discovering the pathway for sensing oxygen. It boasts an impact factor of 5.008 between the year 2015 and 2016. Additionally, it has a five-year impact factor of 5.415. It also ranked top on the total number of published documents among oncology journals between 2015 and 2016. It has been previously listed as the number one oncology journal, beating many other paid subscription newsletters.This traditional journal has passionate editors who not only ensure the journal provides trustworthy information but also that which is up to date. Its popularity is giving specialists a platform to publish their peer reviews and subsequently make significant contributions in their various fields.
The Oncotarget is an online journal that aims at providing insightful knowledge about the oncological area. The journal came to existence in 2010, and since then it has helped students, educators, and health specialist by being a source of knowledge. This journal ensures that scientific discoveries are distributed globally at a fast rate. It is peer reviewed by members of the scientific society. Over the years it has received positive reviews from readers.According to a member of the Oncotarget journal the journal has been helpful in helping authors increase the results of their research by providing in depth, punctual and constructive. It is also readily available to all since the site used also does not require paying of any subscription fees. The platform also contains pdf documents that one can download for future reference. The Oncotarget is a weekly journal; this simply proves that it offers recent updated on new therapies that have come into existence.
This journal has been helpful to researchers regarding science advancement. It is under the management of competent scientists who lead various medical research teams. It is through this research that medical specialists can come up with clinical studies to counter the diseases. This journal also has an impressive editorial board that conduct through editing of the work before publication. This board ensures that the articles are academically legit. Through the Oncotarget drugs have been discovered that could treat various infections. Through the information published treatments have been developed.
Some of these treatment are cancer-related treatments that have aided cancer patients improve their quality of life through better management of the disease. It has also enlightened them on other aspects related to their disease without constant attention from their care givers. It has geared the development of anti-cancer agents which have proved to be quite effective in fighting cancerous cells. Some of these include the anti-malaria drugs. The publications also include articles with reviews from patients from the treatments they have received and how it has changed their life experiences. It also contains supporting evidence to back up all the information it publishes.
Much progress has been made in the last 50 years of cancer treatment. While the medical establishment is still a long way from a cure, one of the most productive areas of cancer treatment innovation has been in the area of what are known as targeted therapies. These drugs are able to specifically target malignant cells, using fiendishly clever bio-engineering technology, and, thus, avoid the release of toxins into the patient’s bloodstream. This class of drugs has dramatically increased the effectiveness of treatment for some types of cancers, such as non-Hodgekin’s lymphoma, and promises to all but eliminate the horrible side effects of chemotherapies used in many other types of cancer.
But now, there is another revolution in cancer treatment brewing. The marriage of Big Data with molecular biology promises to dramatically increase the effectiveness of many types of cancer treatment. This is the custom treatment revolution. Just like the targeted therapy revolution tailors drugs to attack a very narrow, specific type of cell, the custom treatment revolution promises to target a very narrow, specific type of patient. The idea is to reduce the huge amounts of collateral damage that inevitably follow from administering highly toxic treatments to large groups of undifferentiated patients.
One man, Eric Lefkofsky, is at the forefront of this new frontier in cancer research. In 2016, the serial entrepreneur founded Tempus, a company dedicated to the real-time analysis of large amounts of data for oncologists to use in custom tailoring patient treatments. Part of Tempus’ treatment model relies on the vast stores of data provided by the cheap sequencing of human genomes. This, combined with electronic medical records, study data, and other sources of medical data, will be combined with a sophisticated analytic engine, allowing for oncologists to create patient-specific treatments in real time. Eric Lefksofsky predicts that, within ten years, practically no two patients with the same cancer diagnosis will receive the same treatment. Compare that with today, where practically all patients with the same diagnosis get the same drugs in the same regimen.
This new, infinite granularity in how oncologists understand patient and treatment profiles may lead the way to a virtual cure.
About Eric Lefkofsky : www.bizjournals.com/chicago/news/2017/04/12/groupon-co-founder-moves-to-help-youth-access-art.html